Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
ENGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.65 - $11.00
Previous CloseN/A
Volume16.79K
Average Volume (3M)87.82K
Market Cap
$222.82M
Enterprise Value$19.12M
Total Cash (Recent Filing)$217.39M
Total Debt (Recent Filing)$25.36M
Price to Earnings (P/E)―
Beta-1.68
Next Earnings
Sep 16, 2025EPS Estimate
-0.5Last Dividend Ex-Date
Feb 02, 2015Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding51,105,200
10 Day Avg. Volume58,688
30 Day Avg. Volume87,817
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue39.83
Enterprise Value/Gross Profit-382.32
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$22.67Price Target Upside419.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentStrong enrollment in the pivotal cohort of the LEGEND study and expanded clinical sites in the EU and Asia highlight the progress in clinical development for detalimogene.
Financial PositionENGN ended the period with $251.5 million in cash and equivalents, expected to fund operations into 2027, ensuring financial stability.
Regulatory ProgressFeedback from EMA indicates potential for a Conditional Marketing Authorization application for detalimogene, assuming a positive benefit-risk ratio.
Bears Say
Financial PerformanceENGN reported a net loss per share of ($0.51) compared to the consensus of ($0.50), which may raise concerns about financial performance.
Price Target AdjustmentThe price target was reduced from $16 to $14, indicating a more cautious outlook on stock performance.
Research And Development CostsResearch and Development costs of $20.0 million were above the consensus of $12.4 million, indicating higher than expected spending.
enGene Holdings News
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $2.65 and its highest was $11.00 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $222.82M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Sep 16, 2025 which is in 18 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Jun 12, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.497 by -$0.013.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings pays a Quarterly dividend of $0.13 which represents an annual dividend yield of N/A. See more information on enGene Holdings dividends here
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.5.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 51,105,200 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.497. Following the earnings report the stock price went up 0.932%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
enGene Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.67 (419.95% Upside)
$22.67 (419.95% Upside)
Blogger Sentiment
Bearish
ENGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.71%
12-Months-Change
Fundamentals
Return on Equity
-33.97%
Trailing 12-Months
Asset Growth
-2.51%
Trailing 12-Months
Company Description
enGene Holdings
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
ENGN Stock 12 Month Forecast
Average Price Target
$22.67
▲(419.95% Upside)
Technical Analysis
Ocugen
―
Cidara Therapeutics
―
Corvus Pharmaceuticals
―
Tevogen Bio Holdings
―
CARGO Therapeutics, Inc.
―
Ownership Overview
19.16% Insiders
0.27% Mutual Funds
67.00% Other Institutional Investors
13.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---